Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

BACKGROUND: Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method t...

Descripción completa

Detalles Bibliográficos
Autores principales: Germanó, María José, Lozano, Esteban Sebastián, Sanchez, María Victoria, Bruna, Flavia Alejandra, García-Bustos, María Fernanda, Sosa Lochedino, Arianna Lourdes, Salomón, María Cristina, Fernandes, Ana Paula, Mackern-Oberti, Juan Pablo, Cargnelutti, Diego Esteban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Oswaldo Cruz, Ministério da Saúde 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357544/
https://www.ncbi.nlm.nih.gov/pubmed/32667458
http://dx.doi.org/10.1590/0074-02760200067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357544/
https://www.ncbi.nlm.nih.gov/pubmed/32667458
http://dx.doi.org/10.1590/0074-02760200067

Ejemplares similares